1. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
- Author
-
Razak, A.R.A., Wang, H.M., Chang, J.Y., Ahn, M.J., Munster, P., umenschein G, J.r. Bl, Solomon, B., Lim, D.W., Hong, R.L., Pfister, D., Saba, N.F., Lee, Shan Qi, Herpen, C.M. van, Quadt, C., Bootle, D., Blumenstein, L., Demanse, D., Delord, J.P., Razak, A.R.A., Wang, H.M., Chang, J.Y., Ahn, M.J., Munster, P., umenschein G, J.r. Bl, Solomon, B., Lim, D.W., Hong, R.L., Pfister, D., Saba, N.F., Lee, Shan Qi, Herpen, C.M. van, Quadt, C., Bootle, D., Blumenstein, L., Demanse, D., and Delord, J.P.
- Abstract
Contains fulltext : 299624.pdf (Publisher’s version ) (Open Access), BACKGROUND: Alpelisib in combination with cetuximab showed synergistic anti-tumour activity in head and neck squamous cell carcinoma (HNSCC) models. OBJECTIVES: The recommended phase 2 dose (RP2D) was determined in a phase 1b dose-escalation study. Phase 2 evaluated anti-tumour activity with a randomised part in cetuximab-naïve patients and a non-randomised part in cetuximab-resistant patients. PATIENTS AND METHODS: Alpelisib was administered in 28 d cycles as whole tablets, suspension from crushed tablets or suspension from dispersible tablets in patients with platinum-resistant, recurrent/metastatic HNSCC. RESULTS: The RP2D determined for alpelisib was 300 mg/d. Alpelisib-cetuximab achieved an overall response rate of 25% and 9.9% and disease control rate of 75% and 43.7% in phase 1b and phase 2 studies, respectively. Median progression-free survival (PFS) per central review was 86 d for combination treatment and 87 d for cetuximab monotherapy (unadjusted HR 1.12; 95% CI 0.69-1.82; P > 0.05). When adjusted for baseline covariates [sum of longest diameters from central data, haemoglobin and white blood cell (WBC), the results favoured combination treatment (adjusted HR 0.54; 95% CI 0.30-0.97; P = 0.039). PFS per investigator assessment resulted in an unadjusted HR of 0.76 (95% CI 0.49-1.19; P > 0.05) favouring combination treatment. The median PFS in cetuximab-resistant patients was 3.9 months. CONCLUSIONS: The addition of alpelisib to cetuximab did not demonstrate a PFS benefit in cetuximab-naïve patients with advanced HNSCC. The alpelisib-cetuximab combination showed moderate activity in cetuximab-resistant patients, with a consistent safety profile. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01602315; EudraCT 2011-006017-34., 01 november 2023
- Published
- 2023